Loading
Surgery Partners, Inc. Stock: price and insider trades · United States
1 insider bought €263k of shares over the last 90 days, the latest filed 20 Aug 2026.
Surgery Partners, Inc.: what insiders have been doing
Every trade that managers of Surgery Partners, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in United States. Over the twelve months to 18 October 2026, 22 filings were filed, from 13 insiders.
Purchases and sales both appear in the filings: 2 purchases (1 insider, €263k) and 10 sales (6 insiders, €971k). The net balance comes to €708k on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €222k, sold by Evans Jason Eric and made public on 16 March 2026. Among those who bought: 1 senior executive.
The clock since the last published purchase (20 August 2026) now reads 58 days. Typically, a trade is published a median of 4 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Across the 5,812 companies tracked on its exchange, the median is 19 filings; at 22 filings, this issuer sits above that mark. Since 2021, the database holds 5 purchases and 124 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 3.31 bn USD and net income at -77.9 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
216
Thresholds
n/a
Buy Volume
€1M
5 ops. · all time
Sell Volume
€269M
124 ops. · all time
Who traded when
BuySaleDanielle Burkhalter5 sales
David T. Doherty5 sales
Jennifer Baldock4 sales
Marissa Brittenham4 sales
Harrison R. Bane3 sales
Jason Eric Evans3 sales
+3 other insiders
Since the insiders bought
- +2.1%Entry US$14.52 · Close 14 Oct 2026 US$14.83
- +19.1%Entry US$27.49 · Close at T+365 US$32.75
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Surgery Partners, Inc. Buy (bullish), based on 11 analysts. Average price target: US$18.82.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 16,829 of 24,148 companies
38.5
score / 100
Value53
Quality25
FCF yld10%
Earn yld-4.1%
EV/EBITDA10.5x
ROE2.3%
Gross mgn23%
Net mgn-2.4%
Debt/EBITDA7.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$14.55
Analyst consensus
11 analystsBuy
US$14.00Target US$18.82(+29%)US$24.00
Income statement
RevenueUS$3.3B
Gross profitUS$765M23% margin
EBITDAUS$565.5M17% margin
Net income-US$77.9M-2.6% margin
Valuation
PER (forward)52.0x
P/Book1.1x
Beta1.91
Balance sheet & cash
Market capUS$1.9B
Total debtUS$4B
Free Cash FlowUS$195.6M
Debt / Equity117%
Profitability & ownership
ROE2.3%
ROA3.7%
% insiders1.8%
% institutions121.3%
Last declaration on 20 August 2026
Declarations216 total
11,250 shares@ US$14.330.0083% mcap5.8% of flowCommon StockSEC:0001638833-26-000081:0
Canonical exit: 16 Nov 2026 (T+90)
10,000 shares@ US$14.350.0074% mcap5.1% of flowCommon StockSEC:0001638833-26-000079:0
Canonical exit: 16 Nov 2026 (T+90)
34,364 shares@ US$14.550.024% mcap0.1% of flowCommon StockSEC:0001638833-26-000066:0
11,670 shares@ US$13.710.0076% mcap0.0% of flowCommon StockSEC:0001638833-26-000064:0
11,670 shares@ US$13.710.0076% mcap19.0% of flowCommon StockSEC:0001638833-26-000060:0
11,670 shares@ US$13.710.0076% mcap100.0% of flowCommon StockSEC:0001638833-26-000059:0
11,670 shares@ US$13.710.0076% mcap49.6% of flowCommon StockSEC:0001638833-26-000061:0
11,670 shares@ US$13.710.0076% mcap19.0% of flowCommon StockSEC:0001638833-26-000062:0
11,670 shares@ US$13.710.0076% mcap5.7% of flowCommon StockSEC:0001638833-26-000058:0
3,469 shares@ US$12.836.2% of flowCommon StockSEC:0001638833-26-000034:0
8,867 shares@ US$12.501.9% of flowCommon StockSEC:0001638833-26-000032:0
20,400 shares@ US$12.471.7% of flowCommon StockSEC:0001638833-26-000031:0
5,798 shares@ US$13.171.1% of flowCommon StockSEC:0001638833-26-000030:0
3,657 shares@ US$12.542.4% of flowCommon StockSEC:0001638833-26-000033:0
11,462 shares@ US$13.791.1% of flowCommon StockSEC:0001638833-26-000024:0
14,574 shares@ US$13.843.4% of flowCommon StockSEC:0001638833-26-000023:0
42,523 shares@ US$14.118.5% of flowCommon StockSEC:0001638833-26-000022:0
7,736 shares@ US$13.6014.7% of flowCommon StockSEC:0001638833-26-000021:0
272 shares@ US$13.930.8% of flowCommon StockSEC:0001638833-26-000020:0
8,785 shares@ US$13.706.2% of flowCommon StockSEC:0001638833-26-000019:0
42,523 shares@ US$14.1132.5% of flowCommon StockSEC:0001638833-26-000018:0
77,736 shares@ US$16.0867.5% of flowCommon StockSEC:0002100574-26-000003:0
5,726 shares@ US$22.483.9% of flowCommon StockSEC:0001638833-25-000151:0
00Common StockSEC:0001638833-25-000146:0
▼
Same trade as the filing by Patricia Anne Maryland, counted once · View ↗
20,018 shares@ US$22.7416.3% of flowCommon StockSEC:0001638833-25-000145:0
25 of 216 declarations
About Surgery Partners, Inc.
Surgery Partners, Inc. (NASDAQ: SGRY) is a U.S.-based healthcare services company focused on outpatient surgery and short-stay surgical care. Headquartered in Brentwood, Tennessee, in the United States, the company has built a physician-centric operating model designed to deliver efficient, cost-effective surgical care while maintaining clinical quality. Founded in 2004, Surgery Partners expanded through a mix of organic growth and acquisitions and has become one of the larger independent surgical services platforms in the U.S. market. ([ir.surgerypartners.com](https://ir.surgerypartners.com/news-releases/news-release-details/surgery-partners-inc-announces-fourth-quarter-and-full-year-2025?utm_source=openai))
Its asset base is diversified across ambulatory surgery centers (ASCs), surgical hospitals, multi-specialty physician practices, and urgent care facilities. This mix gives the company exposure to multiple points along the patient journey and supports a more integrated delivery model for physicians and patients. Surgery Partners also emphasizes ancillary services, including anesthesia and multi-specialty clinical support, which helps it broaden its service offering and participate in higher-acuity procedures where appropriate. ([ir.surgerypartners.com](https://ir.surgerypartners.com/news-releases/news-release-details/surgery-partners-inc-announces-fourth-quarter-and-full-year-2025?utm_source=openai))
Read moreShow less
From a competitive standpoint, Surgery Partners is positioned in a structurally attractive segment of U.S. healthcare. The ongoing shift of procedures from inpatient hospitals to lower-cost outpatient settings remains a key industry tailwind, and the company’s scale, national footprint, and specialization in short-stay surgery are central to its market position. Management indicates the company operates more than 250 locations across 30 states, giving it meaningful geographic reach while still remaining squarely focused on the United States. That footprint helps Surgery Partners compete with larger health systems and other independent ASC operators. ([ir.surgerypartners.com](https://ir.surgerypartners.com/investor-overview?utm_source=openai))
Recent developments have been notable. In the first quarter of 2026, Surgery Partners reported revenue growth of 4.5% and reaffirmed full-year 2026 guidance calling for at least $530 million of Adjusted EBITDA and revenue of $3.35 billion to $3.45 billion. In March 2026, the company also announced a share repurchase program. In addition, the stock has been a strategic focus: in January 2025, Surgery Partners confirmed receipt of a non-binding acquisition proposal from Bain Capital for the shares it did not already own. Together, these events highlight both the company’s operational momentum and the market’s strategic interest in its outpatient surgery platform. ([ir.surgerypartners.com](https://ir.surgerypartners.com/news-releases/news-release-details/surgery-partners-inc-announces-first-quarter-2026-results?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
